I
started a program to develop new antimicrobials and to study mechanism of
resistance. This program is formally titled 'Taskforce to study Resistance
Emergence & Antimicrobial discovery Technology' or TREAT. Birthday of TREAT
= 24 March 2013
MISSION
1.
DEVELOP NEW ANTIMICROBIALS: There is an immense need for new
antimicrobials that are effective against bacterial strains that are either
susceptible or resistant to currently available drugs. Our aim is to make
necessary effort to systematically develop new drug. This will include chemical
synthesis of new compounds, their evaluation in vitro, in animal models and in
human clinical trials.
2.
STUDY MOLECULAR MECHANISM BY WHICH
BACTERIA RESIST DRUGS:
We will also study the molecular mechanisms used by bacteria to resist drug.
Our focus will be on bacterial pathogens that are important to human health
with the ultimate aim to devise ways to minimize emergence of resistance.
STAGE 1: Multiple number of
independent laboratories, in multiple locations, will be involved in chemical
synthesis of compounds. The groups will have varying interests and expertise in
different classes of compounds. This will maximize our ability to generate a
diverse group of compounds within our focused area. The compounds will then be
submitted to TREAT at Johns Hopkins University. TREAT will make the compounds
available to the microbe group.
STAGE 2: The microbe group will consist of independent laboratories that will focus on microbe(s) of their interest. This will ensure that any compound in TREAT's library will be evaluated against a wide range of microbes.
STAGE 3: Next, any positive activity of a compound will advanced for evaluation in a proper animal model. The chemistry group from which the active compound originated will participate in making required quantities available for evaluation in animal model. Toxicity/ PK/ PD will be evaluated at this stage.
STAGE 4: A compound that is successful in stage 3 will be advanced to stage 4 for clinical trails in humans.
If you are interested you are welcome to inquire about specifics of our program. Our contact email address is treat[at]jhu[dot]edu
STAGE 2: The microbe group will consist of independent laboratories that will focus on microbe(s) of their interest. This will ensure that any compound in TREAT's library will be evaluated against a wide range of microbes.
STAGE 3: Next, any positive activity of a compound will advanced for evaluation in a proper animal model. The chemistry group from which the active compound originated will participate in making required quantities available for evaluation in animal model. Toxicity/ PK/ PD will be evaluated at this stage.
STAGE 4: A compound that is successful in stage 3 will be advanced to stage 4 for clinical trails in humans.
If you are interested you are welcome to inquire about specifics of our program. Our contact email address is treat[at]jhu[dot]edu